Selected article for: "ALT level and ast level"
Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
  • Document date: 2020_3_24
    • ID: 6g34qwer_33
    Snippet: In meplazumab group, the elevation of both ALT and AST (≥ 2 ULN ) was reported in 2 patients (2/17, 11.8%). In control group, both ALT and AST elevations were reported in 1 case (9.1%), and single ALT elevation was reported in 1 case (9.1%). The increased level of ALT and AST returned to normal after 7 days in all four patients, and the treatment procedure was not affected by their fluctuation. The abnormal transaminase was not related with mep.....
    Document: In meplazumab group, the elevation of both ALT and AST (≥ 2 ULN ) was reported in 2 patients (2/17, 11.8%). In control group, both ALT and AST elevations were reported in 1 case (9.1%), and single ALT elevation was reported in 1 case (9.1%). The increased level of ALT and AST returned to normal after 7 days in all four patients, and the treatment procedure was not affected by their fluctuation. The abnormal transaminase was not related with meplazumab treatment after comprehensive judgement by the investigators. No other adverse event was reported in meplazumabtreated patients, including reaction around the injection site, rash, nausea, vomit, anemia, neutropenia, thrombocytopenia, total bilirubin, albumin and creatinine etc.

    Search related documents:
    Co phrase search for related documents
    • adverse event and AST ALT elevation: 1, 2
    • adverse event and AST elevation: 1, 2
    • adverse event and control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and increase level: 1
    • adverse event and injection site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and meplazumab treatment: 1
    • adverse event and normal return: 1
    • ALT elevation and AST ALT elevation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ALT elevation and AST elevation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ALT elevation and control group: 1, 2, 3, 4
    • ALT elevation and normal return: 1
    • AST ALT elevation and control group: 1, 2
    • AST ALT elevation and normal return: 1
    • AST ALT increase level and increase level: 1
    • AST elevation and control group: 1, 2
    • AST elevation and increase level: 1
    • AST elevation and normal return: 1
    • control group and increase level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • control group and injection site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11